Baxter Aktiengesellschaft
Vienna, AU· latest recorded location
Baxter Aktiengesellschaft is named on 7 US grants and 2 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 7
- Published applications
- 2
- Inventors
- 25
- Granted in 2026 so far
- 0
- Most recent grant
- 15 Aug 2006
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 1 | 2 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 2 | 0 |
| 2006 | 2 | 0 |
By publication year.
Technology areas
Share of 9 documents
Recent patents
- Fibrin/fibrinogen-binding conjugate15 Aug 2006US 7,091,325 B2
- Pharmaceutical preparation comprising vWF propeptide28 Feb 2006US 7,005,502 B1
- Alpha 1-antitrypsin preparation as well as a method for producing the same13 Dec 2005US 6,974,792 B2
- Stable factor VIII/vWF-complex2 Aug 2005US 6,924,151 B2
- Method for purifying factor VIII/vWF company by cation-exchange chromatography14 Dec 2004US 6,831,159 B1
Most cited
By later US patents
- Purification of von-Willebrand factor by cation exchanger chromatography15US 6,465,624 B12002
- Pharmaceutical preparation comprising vWF propeptide13US 7,005,502 B12006
- Alpha 1-antitrypsin preparation as well as a method for producing the same12US 6,974,792 B22005
- Direct molecular cloning of foreign genes into poxviruses and methods for the preparation of recombinant proteins9US 6,265,183 B12001
- Fibrin/fibrinogen-binding conjugate7US 7,091,325 B22006